Please Note: Optimal dilutions should be determined by each laboratory for each application.
are available in the Technical Information section on our website.
Preparation and Storage
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Fc Receptor-Like 5 (FCRL5), also known as FcRH5, IRTA2, and CD307, is a 120 kDa protein with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation (1, 2). According to R&D Systems testing, FCRL5 binds to purified human IgG with high affinity. Mature human FCRL5 consists of a 836 amino acid (aa) extracellular domain (ECD) with nine Ig-like domains, a 21 aa transmembrane segment, and a 105 aa cytoplasmic domain with one immunotyrosine activation motif (ITAM) and two immunotyrosine inhibitory motifs (ITIMs) (1, 3). Mouse FCRL5 contains only five Ig-like domains in its ECD. It shares 49% aa sequence identity with human FCRL5 within common regions. Alternate splicing of human FCRL5 generates isoforms that consist of approximately the first one, six, or eight Ig-like domains (3, 4). FCRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood (3, 5‑7). Its ligation inhibits signaling through the B cell antigen receptor (8). Epstein-Barr virus transformation of B cells induces the up‑regulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription (9). The FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies, and the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities (3). FCRL5 is up‑regulated on tumor cells in some types of B cell malignancies (6, 10‑12). In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients (11, 13).
Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
Maltais, L.J. et al. (2006) Nat. Immunol. 7:431.
Hatzivassiliou, G. et al. (2001) Immunity 14:277.
SwissProt # Q96RD9.
Miller, I. et al. (2002) Blood 99:2662.
Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
Vidal-Laliena, M. et al. (2005) Cell. Immunol. 236:6.
Haga, C.L. et al. (2007) Proc. Natl. Acad. Sci. 104:9770.
Mohan, J. et al. (2006) Blood 107:4433.
Ise, T. et al. (2005) Clin. Cancer Res. 11:87.
Ise, T. et al. (2007) Leukemia 21:169.
Kazemi, T. et al. (2009) Cancer Immunol. Immunother. 58:989.
Ise, T. et al. (2006) Clin. Chem. Lab. Med. 44:594.
Have you used Human FCRL5/FCRL3 Alexa Fluor® 750-conjugated Antibody?
Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.